Profound Medical Receives FDA HDE Approval For Sonalleve
Benzinga Newsdesk 5 years ago
BiotechNewsFDAGeneral
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") announced today that Sonalleve® has received U.S. Food and
TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF, TSX:PRN) ("Profound" or the "Company") announced today that Sonalleve® has received U.S. Food and Drug Administration ("FDA") approval under a Humanitarian Device Exemption ("HDE") for the treatment of osteoid osteoma.